<DOC>
	<DOCNO>NCT02127528</DOCNO>
	<brief_summary>study aim verify adequacy dose antibiotic prescribe clinical practice treatment ventilate acquire pneumonia ( VAP ) intensive care unit ( ICU ) pharmacodynamic efficacy criterion consider relevant literature . The impact pharmacodynamic parameter clinical microbiological VAP evaluate .</brief_summary>
	<brief_title>Empiric Antibiotic Therapy Ventilator-acquired Pneumonia With Gram-negative Bacilli Intensive Care</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>1 . Use mechanical ventilation 48 hour 2 . Clinical suspicion ventilationacquired pneumonia ( VAP ) define new radiological persisting infiltrate ( ARDS ) AND one follow feature : purulent tracheal aspirate OR temperature ≥ 38.3°C OR leukocytosis &gt; 10 giga/L 3 . High risk multidrugresistant bacteria , define either least 6 day mechanical ventilation OR antibiotic treatment previous 15 day 4 . Implementation prior distal respiratory sample microbiological diagnosis bronchoalveolar lavage ( BAL ) OR distal sampling protect catheter ( PDP ) 5 . Age ≥ 18 year 6 . Implementing medical examination 7 . Obtain write consent patient , one relative trust person previously designate emergency clause . 1 . Pregnant woman 2 . Expected death within 72 hour diagnosis VAP patient 3 . Dialysis 4 . No affiliation social security scheme ( beneficiary legal ) 5 . Contraindication one class molecule use antibiotic ( βlactam / Fluoroquinolones / Aminoglycosides ) , contain Summary Product Characteristics authorization market .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>